Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > insider filings in mar

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Mar 04, 2021 2:57pm

203 Views

Post# 32717287

RE:insider filings in mar

A user (Calgary) wrote a good writeup at 12:05pm today, scroll down a bit and have a read. I think it helps explain a bit.

Long story short, they arent so much buying as transfering shares between the holdings company and ATE as part of the process for amalgamation. The price per share is not really so important and they are moving them from one to another. I think they have to list a value for it (it seems it may be an average) so thats what you are seeing.

His post really does help explain in detail better than I am doing though.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features